Navigation Links
Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
Date:4/29/2011

x is headquartered in New York City.

Cautionary StatementSome of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

KERYX CONTACT:
Lauren Fischer
Director – Investor Relations
Keryx Biopharmaceuticals, Inc.
Tel: 212.531.5965
E-mail: lfischer@keryx.comKeryx Biopharmaceuticals, Inc.Selected Consolidated Financial Data(In Thousands, Except Share and Per Share Amounts)Statements of Operations Information (Unaudited):Three Months Ended March 31,20112010OPERATING EXPENSES:Research and development:Non-cash compensation

$
259

$
242Other research and development

4,618

2,554Total research and development

4,877

2,796General and administrative:Non-cash compensation

314

407Other general and administrative

1,284

898Total general and administrative

1,598

1,305TOTAL OPERATING EXPENSES6,475

4,101OPERATING LOSS(6,475)

(4,101)OTHER INCOME:Interest and other income, net

70

86NET LOSS$  (6,405)
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the "Company") ... and commercializes proprietary technologies and products for advanced microarray ... the second fiscal quarter ended March 31, 2015. ... advance business with our existing customers and to develop ... CEO of SQI. "The delivery of a fully automated ...
(Date:5/21/2015)... CA (PRWEB) May 21, 2015 ... has announced a partnership with PicnicHealth, a healthcare ... patients. Participants diagnosed with Inflammatory Bowel Disease (IBD) ... as a complementary uBiome research kit. Both companies ... , For more information on ...
(Date:5/21/2015)... 21, 2015  CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced positive updated results from ... for the treatment of unresectable glioblastoma multiforme (GBM), ... multisite trial is designed to investigate the preliminary ... tumors have progressed following prior treatment with surgery, ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
Breaking Biology Technology:SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8uBiome Partners with PicnicHealth 2uBiome Partners with PicnicHealth 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2
... 30 Sinovac Biotech Ltd. (NYSE Amex: ... in China, today announced that the Company has initiated ... the new influenza A (H1N1) strain, Swine Flu, which ... the world. Sinovac has contacted various Chinese government authorities ...
... Outside In" Program to Launch at the Annual Oncology Nursing ... (Nasdaq: AMGN ) and ONS Edge , a ... they will partner alongside celebrity make-up artist and cancer survivor ... with Cancer From the Outside In . The initiative is ...
... Tigris Pharmaceuticals, Inc., a privately held drug development company, ... molecule, AFP-464, during the recent AACR 100th Annual Meeting ... advancement in the treatment of Triple Negative Breast Cancer, ... cancer," stated Edmundo Muniz, M.D., Ph.D., President and Chief ...
Cached Biology Technology:Sinovac Initiates Preparatory Activities for Swine Flu Vaccine 2Sinovac Initiates Preparatory Activities for Swine Flu Vaccine 3Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 2Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 3Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 4Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 5Photos: Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign 6Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 2Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 3Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting 4
(Date:5/21/2015)... , May 21, 2015 ... Imaging Market by Solutions (Hardware, Software, Services), by Applications ... & others), by End-Users (Military & Defense & ... MarketsandMarkets, Thermal Imaging Market is expected to grow ... by 2020, at a Compound Annual Growth Rate ...
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/14/2015)... May 14, 2015 Research and Markets ... "Fingerprint Sensors Market in Smart Mobile Devices " ... believes that 2014 was a watershed year for fingerprint ... of ,Apple Pay,. Apple gave fingerprint sensors a raison ... service. Fingerprint sensors are a must-have feature in flagship ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Global Smart Mobile Devices Fingerprint Sensors Market 2015-2019: Key Vendors are Authentec, Validity Sensors, Fingerprint Cards, Next Biometrics Group. IDEX, and Qualcomm 2
... Anthropogenic CO 2 emissions, in addition to causing ... them to turn progressively acidic. This change has severe ... in the latest edition of the journal Science ... of the Earth,s oceans has undergone profound changes, although none ...
... The American Cancer Society estimates that 44,000 new cases ... 37,000 people will die from the disease. These are not ... to rush through replication and then stops them cold, ... M phase. Healthy cells that don,t rush are unharmed. ...
... from Parkinson,s disease, a disorder of the nervous system ... world,s population ages, it,s estimated that the number of ... several effective therapies that treat Parkinson,s symptoms, nothing slows ... what exactly causes the disease, evidence points to one ...
Cached Biology News:Oceans acidifying faster today than in past 300 million years 2Tortoise and the hare: New drug stops rushing cancer cells, slow and steady healthy cells unharmed 2Parkinson's disease stopped in animal model 2Parkinson's disease stopped in animal model 3
... Receptor (PR) Competitor Assay Kits are ... progesterone receptor binding compounds using fluorescence ... a fusion of glutathione transferase to ... progesterone receptor [PR-LBD(GST)] and a proprietary, ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential CV/Renal liabilities of compounds....
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential Neurological liabilities of compound...
... from a hematopoietic stem cells called monocytes. ... bone surface and lowering the surrounding pH ... The bone mineral is then solubilized and ... is controlled primarily by Macrophage Colony-Stimulating Factor ...
Biology Products: